Biologics

Bone Solutions Inc. announced first 250 cases of its magnesium-based bone void filler OsteoCrete were implanted.

Maryland Technology Development Corp., awarded the first two grants from the state's Stem Cell Research Fund, Baltimore Business Journal reports.

The global orthobiologics market is projected to grow at a 3.5 percent compound annual growth rate, topping $6.5 billion by 2027, according to a Future Market Insights report.

Orthobiologics company Kuros Biosciences named its strategic advisory board.

Reinvent Biologics appointed orthopedic surgeon David Drez Jr., MD, as CMO.

Researchers identified the human skeletal stem cell and derived it from induced pluripotent stem cells, according to findings published in Cell Stem Cell.

Pablo Pazmino, MD, medical director of Spine Cal in Santa Monica, Calif., discusses the key trends in spinal and neurospine technology and how he evaluates new technology for his practice.

R. Brandon Trale, DO, performed a partial hip replacement case as part of a Pluristem Therapeutics stem cell trial at Indiana (Pa.) Regional Medical Center, according to The Indiana Gazette.

NuVasive launched three new biologics offerings for the spine industry.

Cost management solutions company Tempus Innovations partnered with Regenexx to provide reduced-cost, non-surgical treatments to injured workers.